字體大小 * * *
分享到

2019 SPARK Translational Medicine Symposium: Starting with the End in Mind

2019/06/15
Supervised by the Ministry of Science and Technology (MOST) and organized by STPI, the "2019 SPARK Translational Medicine Symposium" was held at the International Conference Center of the National Taiwan University Hospital on May 15.  Five international biomedical product development experts from Stanford SPARK, SPARK Oceania and SPARK Taiwan were invited to discuss issues such as subjects screening, product value creation, drug safety, clinical trial design, emerging digital medical technology and its application and share their valuable experiences.

Group Photo. (From left) Ms. Wang Li-Ru from BioMed Commercialization Center; Dr. Jane SC Tsai, the Senior Vice President for International Affairs, YFY Biotech Management Company; Director General Joung Yuh-Jzer from STPI, Prof. Jane Tseng, the Director of SPARK Taiwan Program; Deputy Minister Hsieh Da-Bin; Mr. Ryan Engen, the AIT Economic Officer; Prof. Michael Wallach from SPARK Oceania; Mr. Michael Taylor, the Founder of NonClinical Safety Assessment; Mr.  Lyn Frumkin, the Advisor from Stanford SPARK
 

The Symposium participants include representatives from six anchor universities (National Taiwan University, National Cheng Kung University, National Yang-Ming University, Taipei Medical University, China Medical University, Fu Jen University and National Chiao Tung University) and local experts and scholars in the field of biotechnology.  Mr. Ryan Engen, the Economic Officer from the American Institute in Taiwan (AIT), also participated in the Symposium to show support on behalf of the US government and recognise the achievement of Taiwan-US bilateral collaboration in science and technology.

 2019 SPARK Translational Medicine Symposium
 

With the efforts of governments, more and more basic researches have been successfully translated into medicines or medical equipment to improve the quality of life of patients. However, the process from research and development to commercialization of pharmaceutical is relatively time-consuming.  It is never easy to cross the "Valley of Death". Mr. Hsieh Da-Bin, the Deputy Minister of the Ministry of Science and Technology, mentioned at the opening ceremony that biotechnology is fundamental for Taiwan in the development of science and technology.  Taiwan has excellent scientific research foundation, excellent biotechnology talents, and rich clinical research experiences.  A well-reputed health insurance database and grounded information technology are crucial to establish a niche for Taiwan's development in the biotechnology industry.

  2019 SPARK Translational Medicine Symposium
 

Supervised by the MOST, STPI’s SPARK Taiwan Office was launched in 2013.  SPARK Taiwan Program imported the successful cultivation mechanism from Stanford SPARK Program to provide training resources based on domestic needs, encourage anchor universities to commercialize research output, and actively cultivate translational talents.  As of today, more than 200 biomedical teams have been trained, 29 startups have been established and 13 cases of technology transfer have been facilitated.

Mr. Ryan Engen, the AIT Economic Officer
 
Dr. Michel Chu giving speech entitled “Commercialization and Value Creation for Life Science”
 
Professor Michael Wallach giving speech entitled “Project Selection & Development in Translational Medicine”